Brooklyn, N.Y., March 10, 2022 — Opentrons Robotics today announced the largest expansion of its automation portfolio to date, launching four new OT-2 workstation products supporting popular applications, including NGS, PCR and protein purification. These launches build on the success of the OT-2 COVID-19 workstations, which have been used by hundreds of labs around the world to rapidly scale reliable, standardized COVID-19 testing and screening workflows. The new workstations comprise the OT-2 platform, application-specific hardware, pipettes and labware, and custom protocol development, quickly allowing any lab to set up automated workflows, at a fraction of the cost of other automation solutions.
The four new workstations are:
“The expansion of our OT-2 portfolio will bring the benefits of radically simple, accessible automation to new customers,” said David Kim, general manager of Opentrons Robotics. “Throughout the pandemic, our automation suite has enabled labs to rapidly pivot into COVID-19 testing, screening and genomic surveillance by using the OT-2 and our modules. Along with their ease of setup, our solutions help labs run more efficiently — through accurate, reproducible results, all in an automated fashion, which frees up scientists’ time. Opentrons’ new workstations will bring all these benefits to scientists working across genomics and proteomics applications.”
“The Opentrons system has enhanced our team’s ability to access purified mRNA reliably and quickly, which is vital for our work developing innovative gene-based therapies,” said Dr. Xinyue Zhang, an investigator at Luye Life Sciences in Massachusetts. “The Opentrons team are very supportive, and they offer custom protocol development, which we utilized for our workflow. Now, preparing mRNA is as easy as loading the reagents, selecting the protocol and then waiting a few hours.”
The OT-2 is a high-precision, open-source personal pipetting robot designed to be easy for scientists to use and flexible enough to automate many application workflows. The robot and its accompanying automation platform are used to automate hundreds of protocols and workflows in genomics, proteomics, cell-based assays and drug discovery.
For more information, visit: https://opentrons.com/
About Opentrons Labworks, Inc.
Opentrons Labworks, Inc., is a disruptive life science company leveraging its integrated lab platform to supercharge the pace of innovation in research and healthcare. Through our business unit, Opentrons Robotics, thousands of institutions are automating R&D operations with flexible, easy-to-use lab robots. Health systems across the US rely on our Pandemic Response Lab (PRL) to deliver high-throughput and affordable molecular diagnostic testing. And through recent acquisitions Neochromosome and Zenith AI, biopharma can benefit from our world-class genome-scale cell engineering solutions. Learn more at https://www.opentronslabworks.com/.
About Opentrons Robotics
Opentrons Robotics, a business unit of Opentrons Labworks, Inc., is the industry leader in flexible, user-friendly automation for life science R&D labs. Opentrons Robotics’ flagship product, the OT-2, can be found in thousands of labs in more than 40 countries. Throughout the COVID-19 pandemic, OT-2 robots have been deployed to hospital labs around the world to test millions of patient samples. Our product line is expanding to offer tailored automation and protocol development for the most common and time-consuming manual processes in molecular biology, including NGS library prep, PCR setup and protein purification. Learn more at https://opentrons.com/.